A61K 48/0083
Medicinal preparations containing genetic material which is inserted into cells of the
Official title: {characterised by an aspect of the administration regime}
A61K48/0083 (Medicinal preparations containing genetic material which is inserted into cells of the) appears on 240 US grants and 708 published applications in this corpus.
Search patents in A61K- Granted patents
- 240
- Published applications
- 708
- Assignees
- 312
- Inventors
- 1,322
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 2 |
| 2002 | 3 | 10 |
| 2003 | 2 | 19 |
| 2004 | 1 | 26 |
| 2005 | 4 | 19 |
| 2006 | 3 | 13 |
| 2007 | 9 | 15 |
| 2008 | 6 | 10 |
| 2009 | 5 | 14 |
| 2010 | 7 | 12 |
| 2011 | 4 | 15 |
| 2012 | 1 | 7 |
| 2013 | 7 | 20 |
| 2014 | 6 | 18 |
| 2015 | 9 | 15 |
| 2016 | 13 | 26 |
| 2017 | 12 | 16 |
| 2018 | 12 | 30 |
| 2019 | 16 | 64 |
| 2020 | 13 | 35 |
| 2021 | 22 | 40 |
| 2022 | 17 | 46 |
| 2023 | 16 | 50 |
| 2024 | 24 | 49 |
| 2025 | 14 | 75 |
| 2026 | 12 | 62 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Viral vector therapy22 Sep 2026US 12,741,036 B2Apellis Pharmaceuticals, Inc.
- Compositions and methods comprising viral vector systems for multiplexed activation of endogenous genes as immunotherapy and viral-based immune-gene therapy4 Aug 2026US 12,697,398 B2Yale University
- Biologic agents and methods of use7 Jul 2026US 12,673,068 B2Sono Thera, Inc.
- Immunomodulating gene therapy26 May 2026US 12,636,302 B2Duke University
- Oligonucleotide compositions and methods thereof26 May 2026US 12,637,672 B2Wave Life Sciences Ltd.
- Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies8 Oct 2026US 2026/0306664 A1AbbVie Inc.
- Aav9-mediated gene therapy for treating mucopolysaccharidosis type i24 Sep 2026US 2026/0284155 A1The Trustees of the University of Pennsylvania
- Methods and system for optogenetic stimulation of adipocytes24 Sep 2026US 2026/0284229 A1MaineHealth
- Single base editing of atnx2 for the treatment of sca217 Sep 2026US 2026/0273101 A1The Children’s Hospital of Philadelphia
- Methods and Compositions for Treating Osteoarthritis10 Sep 2026US 2026/0263499 A1Genascence Corporation
Most cited
By later US patents
- Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor615US 5,328,470 AThe Regents of the University of Michigan · 1994
- Engineered nucleic acids and methods of use thereof372US 8,822,663 B2Moderna Therapeutics, Inc. · 2014
- Controlled release polymer nanoparticle containing bound nucleic acid ligand for targeting120US 7,550,441 B2Massachusetts Institute of Technology · 2009
- Engineered nucleic acids and methods of use thereof91US 9,181,319 B2Moderna Therapeutics, Inc. · 2015
- Controlled release nanoparticle having bound oligonucleotide for targeted delivery87US 7,727,969 B2Massachusetts Institute of Technology · 2010